These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 10547418)

  • 1. Formulation of HIV-envelope protein with lipid vesicles expressing ganglioside GM1 associated to cholera toxin B enhances mucosal immune responses.
    Lian T; Bui T; Ho RJ
    Vaccine; 1999 Nov; 18(7-8):604-11. PubMed ID: 10547418
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cholera toxin B-mediated targeting of lipid vesicles containing ganglioside GM1 to mucosal epithelial cells.
    Lian T; Ho RJ
    Pharm Res; 1997 Oct; 14(10):1309-15. PubMed ID: 9358541
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mucosal immunity to HIV-1: systemic and vaginal antibody responses after intranasal immunization with the HIV-1 C4/V3 peptide T1SP10 MN(A).
    Staats HF; Nichols WG; Palker TJ
    J Immunol; 1996 Jul; 157(1):462-72. PubMed ID: 8683152
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of an internal permissive site in the cholera toxin B-subunit and insertion of epitopes from human immunodeficiency virus-1, hepatitis B virus and enterotoxigenic Escherichia coli.
    Bckström M; Holmgren J; Schödel F; Lebens M
    Gene; 1995 Nov; 165(2):163-71. PubMed ID: 8522171
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intranasal vaccination using interleukin-12 and cholera toxin subunit B as adjuvants to enhance mucosal and systemic immunity to human immunodeficiency virus type 1 glycoproteins.
    Albu DI; Jones-Trower A; Woron AM; Stellrecht K; Broder CC; Metzger DW
    J Virol; 2003 May; 77(10):5589-97. PubMed ID: 12719551
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Strategies for the induction of immune responses at mucosal surfaces making use of cholera toxin B subunit as immunogen, carrier, and adjuvant.
    Holmgren J; Czerkinsky C; Lycke N; Svennerholm AM
    Am J Trop Med Hyg; 1994; 50(5 Suppl):42-54. PubMed ID: 8203723
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mucosal immune response to an HIV C4/V3 peptide following nasal or intestinal immunization of rabbits.
    Winchell JM; Van Kruiningen HJ; Silbart LK
    AIDS Res Hum Retroviruses; 1997 Jul; 13(10):881-9. PubMed ID: 9197382
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mucosal and systemic adjuvant effects of cholera toxin and Cry1Ac protoxin on the specific antibody response to HIV-1 C4/V3 peptides are different and depend on the antigen co-administered.
    Esquivel-Pérez R; Moreno-Fierros L
    Viral Immunol; 2005; 18(4):695-708. PubMed ID: 16359236
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel adjuvant for mucosal immunity to HIV-1 gp120 in nonhuman primates.
    Yoshino N; Lü FX; Fujihashi K; Hagiwara Y; Kataoka K; Lu D; Hirst L; Honda M; van Ginkel FW; Takeda Y; Miller CJ; Kiyono H; McGhee JR
    J Immunol; 2004 Dec; 173(11):6850-7. PubMed ID: 15557179
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of CD80 and CD86 in host immune responses to the recombinant hemagglutinin domain of Porphyromonas gingivalis gingipain and in the adjuvanticity of cholera toxin B and monophosphoryl lipid A.
    Zhang P; Lewis JP; Michalek SM; Katz J
    Vaccine; 2007 Aug; 25(33):6201-10. PubMed ID: 17629367
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Manipulation of intestinal immune responses against ovalbumin by cholera toxin and its B subunit in mice.
    Van der Heijden PJ; Bianchi AT; Dol M; Pals JW; Stok W; Bokhout BA
    Immunology; 1991 Jan; 72(1):89-93. PubMed ID: 1705237
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined HIV-1 Envelope Systemic and Mucosal Immunization of Lactating Rhesus Monkeys Induces a Robust Immunoglobulin A Isotype B Cell Response in Breast Milk.
    Nelson CS; Pollara J; Kunz EL; Jeffries TL; Duffy R; Beck C; Stamper L; Wang M; Shen X; Pickup DJ; Staats HF; Hudgens MG; Kepler TB; Montefiori DC; Moody MA; Tomaras GD; Liao HX; Haynes BF; Ferrari G; Fouda GGA; Permar SR
    J Virol; 2016 May; 90(10):4951-4965. PubMed ID: 26937027
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Humoral immune responses by prime-boost heterologous route immunizations with CTB-MPR(649-684), a mucosal subunit HIV/AIDS vaccine candidate.
    Matoba N; Geyer BC; Kilbourne J; Alfsen A; Bomsel M; Mor TS
    Vaccine; 2006 Jun; 24(23):5047-55. PubMed ID: 16621185
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mucosal and systemic antibody responses against an acellular pertussis vaccine in mice after intranasal co-administration with recombinant cholera toxin B subunit as an adjuvant.
    Isaka M; Yasuda Y; Taniguchi T; Kozuka S; Matano K; Maeyama J; Morokuma K; Ohkuma K; Goto N; Tochikubo K
    Vaccine; 2003 Mar; 21(11-12):1165-73. PubMed ID: 12559794
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neutralization of HIV-1 by secretory IgA induced by oral immunization with a new macromolecular multicomponent peptide vaccine candidate.
    Bukawa H; Sekigawa K; Hamajima K; Fukushima J; Yamada Y; Kiyono H; Okuda K
    Nat Med; 1995 Jul; 1(7):681-5. PubMed ID: 7585151
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Whole cholera toxin and B subunit act synergistically as an adjuvant for the mucosal immune response of mice to keyhole limpet haemocyanin.
    Wilson AD; Clarke CJ; Stokes CR
    Scand J Immunol; 1990 Apr; 31(4):443-51. PubMed ID: 2333468
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhanced mucosal and systemic immune response with intranasal immunization of mice with HIV peptides entrapped in PLG microparticles in combination with Ulex Europaeus-I lectin as M cell target.
    Manocha M; Pal PC; Chitralekha KT; Thomas BE; Tripathi V; Gupta SD; Paranjape R; Kulkarni S; Rao DN
    Vaccine; 2005 Dec; 23(48-49):5599-617. PubMed ID: 16099080
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential induction of mucosal and systemic antibody responses in women after nasal, rectal, or vaginal immunization: influence of the menstrual cycle.
    Kozlowski PA; Williams SB; Lynch RM; Flanigan TP; Patterson RR; Cu-Uvin S; Neutra MR
    J Immunol; 2002 Jul; 169(1):566-74. PubMed ID: 12077289
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CTA1-DD adjuvant promotes strong immunity against human immunodeficiency virus type 1 envelope glycoproteins following mucosal immunization.
    Sundling C; Schön K; Mörner A; Forsell MNE; Wyatt RT; Thorstensson R; Hedestam GBK; Lycke NY
    J Gen Virol; 2008 Dec; 89(Pt 12):2954-2964. PubMed ID: 19008380
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Immunopotency of the recombinant urease B subunit vaccine of Helicobacter pylori after intranasal administration to mice].
    Gao ZG; Zou QM; Guo G; Guo TS; Zou QM; Zeng WK; Xie QH
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2003 Jan; 19(1):68-70. PubMed ID: 15132912
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.